Country: New Zealand
Language: English
Source: Medsafe (Medicines Safety Authority)
Glyceryl trinitrate 18mg (as 5mg /24h)
iNova Pharmaceuticals (New Zealand) Limited
Glyceryl trinitrate 18 mg (as 5mg /24h)
5 mg/24h
Transdermal patch
Active: Glyceryl trinitrate 18mg (as 5mg /24h) Excipient: Ethyl oleate Glyceryl monolaurate IOA/ACM Copolymer
Sachet, laminate, 30 patches
Prescription
Prescription
Copperhead Chemical Company Inc
Package - Contents - Shelf Life: Sachet, laminate, - 30 patches - 36 months from date of manufacture stored at or below 25°C
1988-11-24
Medsafe Logo INFORMATION FOR CONSUMERS Home | Consumers | Health Professionals | Regulatory | Other | Hot Topics | Search Consumer Medicine Information MINITRAN™ 5 and 10 glyceryl trinitrate 5mg and 10mg Transdermal Delivery System What is in this leaflet This leaflet answers some common questions about Minitran patches. However it does not contain all the available information. Your doctor or pharmacist have more detailed information about Minitran patches. So if you need more information about Minitran please ask your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risk of you using Minitran patches against the benefits it can have for you. If you have any concerns about using Minitran please ask your doctor or pharmacist. Keep this leaflet with the medicine. You may want to read it again. What MINITRAN is used for Minitran patches are used to help prevent attacks of angina (chest pain). The active ingredient, glyceryl trinitrate, belongs to a group of medicines called nitrates. When a Minitran patch is placed on the skin, glyceryl trinitrate passes slowly through the skin and into the blood stream. Glyceryl trinitrate works by widening blood vessels, letting more blood and oxygen reach the heart. Your doctor may prescribe Minitran for another purpose. If you are not sure why you are using this medicine please ask your doctor. Before using MINITRAN When you must not use MINITRAN Do not use Minitran if: you are allergic to any of the ingredients listed under "Product Description" or to any you are allergic to any of the ingredients listed under "Product Description" or to any medicine or food containing nitrates or nitrites. If you have an allergic reaction you may get a skin rash, difficulty Read the complete document
Medsafe Logo INFORMATION FOR HEALTH PROFESSIONALS Home | Consumers | Health Professionals | Regulatory | Other | Hot Topics | Search Data Sheet MINITRAN™ 5 Nitroglycerin USP 18 mg per transdermal patch MINITRAN™ 10 Nitroglycerin USP 36 mg per transdermal patch Presentation MINITRAN 5 Transdermal Delivery System is a clear elliptical patch of 6.7cm² medical tape containing Nitroglycerin USP 18 mg in a hypoallergenic, medical grade, acrylate-based polymer adhesive matrix. Glyceryl trinitrate 5 mg is released directly from the matrix over 24 hours. MINITRAN 10 Transdermal Delivery System is a clear elliptical patch of 13.3cm² medical tape containing Nitroglycerin USP 36 mg in a hypoallergenic, medical grade, acrylate-based polymer adhesive matrix. Glyceryl trinitrate 10 mg is released directly from the matrix over 24 hours. The rate of release of glyceryl trinitrate is proportional to the area of the patch applied to the skin. Approximately 0.75 mg glyceryl trinitrate is released per 24 hours for every square centimetre of patch area. Each patch is packaged in a paper laminate pouch. Uses Actions When a MINITRAN patch is applied to the skin, glyceryl trinitrate is absorbed continuously through the skin into the systemic circulation. This results in active medication reaching the target organs (heart, vascular system) before deactivation by the liver. Glyceryl trinitrate is a smooth muscle relaxant with vascular effects manifested predominantly by venous dilation with pooling. The major beneficial effect of glyceryl trinitrate in angina pectoris is a reduction in myocardial oxygen consumption secondary to of glyceryl trinitrate in angina pectoris is a reduction in myocardial oxygen consumption secondary to vascular dilation with resultant reduction in car Read the complete document